Click Therapeutics, Medical Clinic, New York, USA

Click Therapeutics, Inc. is at the forefront of integrating software into medical treatments. Founded in 2012 by David Benshoof Klein, the company has developed a platform that combines neuroscience with technology to create Digital Therapeutics™—software applications prescribed by physicians to treat various medical conditions.

Mission and Vision

Click’s mission is to provide patients with access to safe and effective digital treatments, aiming to bridge gaps in traditional healthcare by offering scalable and personalized interventions. The company’s vision is to redefine modern medicine by delivering software-based treatments that can be prescribed alongside or instead of conventional therapies.

Product Portfolio

1. CT-101 (Clickotine™): A prescription digital therapeutic designed to aid in smoking cessation. It combines behavioral therapy with neuromodulatory techniques to help users quit smoking.

2. CT-132: An investigational digital therapeutic aimed at preventing episodic migraines. It recently met its primary endpoint in the ReMMi-D pivotal trial, demonstrating a reduction in monthly migraine days.

3. CT-155: Developed in collaboration with Boehringer Ingelheim, this digital therapeutic targets the negative symptoms of schizophrenia. It has received FDA Breakthrough Device designation and is undergoing a pivotal clinical trial.

4. CT-102: In partnership with Indivior, Click is developing this digital therapeutic to treat Opioid Use Disorder. It combines evidence-based behavioral therapy with personalized neuromodulatory interventions.

Click SE™: Software-Enhanced Drugs

Click has introduced Click SE™, a novel approach that combines pharmacotherapy with digital therapeutics. This integration aims to enhance the clinical benefits of medications by providing personalized, software-driven interventions alongside traditional drug treatments. The FDA is currently considering draft guidance on Prescription Drug-Use Related Software (PDURS), which could pave the way for such integrated therapies to be prescribed together.

Technology Platform

At the core of Click’s offerings is its AI-enabled platform, Clickometrics®. This platform personalizes user experiences by continuously adapting to individual behaviors and needs, optimizing engagement and therapeutic outcomes. It supports the development of digital therapeutics across various medical conditions, ensuring that treatments are tailored to each patient’s unique requirements.

Collaborations and Partnerships

Click has established strategic collaborations with leading pharmaceutical companies to expand the reach and impact of its digital therapeutics:

• Otsuka Pharmaceutical: In partnership with Otsuka, Click developed the first FDA-cleared prescription app for the adjunctive treatment of Major Depressive Disorder symptoms.

• Indivior: The collaboration with Indivior focuses on developing digital therapeutics for substance use disorders, starting with Opioid Use Disorder.

• Boehringer Ingelheim: Together, Click and Boehringer Ingelheim are working on digital therapeutics for schizophrenia, with CT-155 receiving FDA Breakthrough Device designation.

Future Directions

Click Therapeutics continues to explore new therapeutic areas and expand its portfolio of digital therapeutics. The company is actively engaged in clinical trials and regulatory processes to bring its innovative treatments to market. With the evolving landscape of digital health, Click is well-positioned to lead the integration of software into medical treatments, offering patients accessible and effective alternatives to traditional therapies.

Click Therapeutics is redefining the future of medicine by developing software-based treatments that complement or replace conventional therapies. Through its innovative approach, strategic partnerships, and commitment to patient-centered care, Click is setting new standards in treating various medical conditions, paving the way for a more personalized and accessible healthcare system.

Key Facts Table